TABLE 5.
Cost‐effectiveness of treatment strategies for hepatitis C virus infection among kidney waitlist by availability of HCV+ organs (HCV+ candidates transplanted more quickly)
| Treatment strategy | Cost, $ | Incremental cost, $ |
QALM | Incremental QALM |
ICER, $/ QALY |
Undiscounted life months |
5 y budget impact, $ |
|---|---|---|---|---|---|---|---|
| 6 mo diff. | |||||||
| Treat posttransplant | 700 700 | 59.3 | 162.5 | 412 996 200 | |||
| Treat pretransplant | 736 000 | 35 300 | 65.2 | 5.9 | 71 500 | 164.2 | 423 081 000 |
| 9 mo diff. | |||||||
| Treat posttransplant | 690 700 | 60.4 | 163.5 | 407 400 300 | |||
| Treat pretransplant | 734 900 | 44 200 | 65.3 | 5.0 | 107 100 | 164.3 | 421 939 000 |
| 12 mo diff. | |||||||
| Treat posttransplant | 682 400 | 61.8 | 164.8 | 383 726 900 | |||
| Treat pretransplant | 735 700 | 53 300 | 65.6 | 3.9 | 162 800 | 164.5 | 416 710 300 |
| 18 mo diff. | |||||||
| Treat posttransplant | 658 300 | 63.9 | 167.1 | 386 909 800 | |||
| Treat pretransplant | 730 900 | 72 500 | 65.7 | 1.8 | 489 000 | 164.8 | 413 829 900 |
| 24 mo diff. | |||||||
| Treat posttransplant | 634 000 | 66.5 | 169.4 | 374 017 500 | |||
| Treat pretransplant | 725 600 | 91 600 | 66.11 | −0.3 | Dom | 165.3 | 407 602 500 |
Dom, dominated (more costly and less effective); QALM, quality‐adjusted life month; ICER, incremental cost‐effectiveness ratio; QALY, quality‐adjusted life year.